Honored as one of the “Top 10 Legal Innovators of the Year in Europe”.Financial Times – European Innovative Lawyers Awards 2014

Henning C. Schneider

  • Warburgstrasse 50
  • 20354 Hamburg
  • Germany

Dr. Henning C. Schneider is a partner in the Hamburg office of Latham & Watkins, Co-chair of the German Corporate Department and Chair of the firm’s global Healthcare Industry Group. He is member of several supervisory boards and President of the American Chamber of Commerce, Northern Chapter. Mr. Schneider is an Alumnus of the German National Academic Foundation (Studienstiftung des Deutschen Volkes).

He focuses on advising international and national corporates, PE investors and public organizations on:

  • M&A/PE transactions
  • Joint ventures, Restructurings, Carve-outs and Privatizations    

He offers broad industry expertise in Healthcare/Life Sciences, Financial Services, Infrastructure, Automotive, Real Estate and Energy/Cleantech.

Mr. Schneider led the team on Rhön-Klinikum’s €3 billion sale of major assets to Fresenius/Helios, which was honored by The Lawyer as “European Corporate Deal of the Year 2015.” Financial Times European Lawyers Awards 2014 listed him as one of the “Top 10 Legal Innovators of the Year in Europe” and he is one of the “best lawyers” for Corporate/M&A in Germany (Handelsblatt Best Lawyers 2016).

JUVE 2016/2017 lists Mr. Schneider as a “recommended lawyer” for M&A, Corporate Law and Healthcare. Clients are “very impressed” (2013/2014). He is also praised for his “excellent and timely advice” and as “highly competent, flexible, thinks strategically and has pronounced commercial understanding” (2012/2013).

Chambers Europe Germany recognizes him as a “key individual” for M&A and Healthcare. Sources describe him as “very intelligent, with a good attitude in negotiations“ and  clients appreciate that he is “very well connected within the healthcare arena and a helpful intermediary to other contacts in the industry, enjoying the trust of the main stakeholders“ (2017); he is considered as “one of the most important advisers for hospital deals” (2016). Clients praise: “He has a deep knowledge of corporate law, but also the mindset to understand clients’ commercial needs” (2015). Furthermore, “he has a very deep knowledge of all questions of legal importance in a transaction – he concentrates on the sector, so you don’t have to start from zero when you work together” (2014).

The Legal 500 mentions his “impressive presence in large transactions in healthcare and life sciences,” praises the “high-profile team around Henning Schneider” (Germany 2014) and names him “a heavyweight both in legal terms as well as in strategy” (EMEA 2013).

Mr. Schneider has published various articles in legal and business magazines and is the coauthor of:

  • “Grabitz/Hilf/Nettesheim, Das Recht der Europäischen Union: EUV/AEUV,” C.H.Beck, 63rd edition, 2017
  • “Münchener Handbuch des Gesellschaftsrechts,” C.H.Beck, volumes 1 and 2, 4th/5h edition, 2016

Dr. Schneider’s experience includes advising/representing:

  • Aurubis AG on its bid for several copper mines and smelters
  • Bankhaus Lampe (Oetker-Group) on auction for acquisition of BHF Bank from Deutsche Bank AG and for acquisition of LGT Bank
  • Berenberg Bank and Bankhaus Lampe on the sale of Universal-Investment, the fourth largest German investment company, to Montague
  • Capgemini on acquisition of CS Consulting
  • Carlyle on its acquisitions of Alloheim Group and of Ameos AG
  • DAK Krankenkasse on merger with BKK Gesundheit and on merger with BKK Axel Springer
  • Delphi Automotive on sale of Thermal Business to Mahle (US$700 million)
  • DPE Deutsche Private Equity on acquisition of Zellbios Group
  • Dubai Ports/DP World on auction to acquire 49% in HHLA Hamburger Hafen und Logistik AG (€2.5 billion)
  • Hapag-Lloyd AG Konsortium on acquisition of Hapag-Lloyd AG from TUI AG (€4.45 billion)
  • Novo A/S on the strategic investment in Evotec AG
  • Q-Cells SE on the sale to Hanwha Corporation, South Korea
  • Rhön-Klinikum AG on its sale of major assets (e.g. 40 hospitals) to Dax listed Fresenius (€3.14 billion) and on share buyback
  • Sana Kliniken AG on acquisition of Regio Kliniken
  • Shareholders of Hanse Chemie AG/Nanoresins AG on sale to Evonik AG
  • Siemens AG on several projects
  • Sparkasse Frankfurt, Sparkasse KölnBonn, Sparkasse Düsseldorf on sale of Corpus Sireo to Swiss Life
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.